Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)

NCT04952337 is registered in ClinicalTrials.gov with Hannover Medical School as lead sponsor.

NCT NCT04952337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Lead sponsor
Hannover Medical School
Phase
Observational
Overall status
Unknown status
Start date
October 1, 2020
Completion date
July 1, 2022
Enrollment
400 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

bacterial pneumonia, covid-19, pneumonia due to h. influenzae, pneumonia due to other specified infectious organisms, pneumonia due to streptococcus pneumoniae, pneumonia in diseases classified elsewhere, pneumonia, organism unspecified, viral pneumonia